In a research report issued today, MLV analyst Arlinda Lee maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) with a $20 price target, after the …
In a research report issued today after market close, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on shares of Halozyme Therapeutics, Inc.
In a research report sent to investors this morning, MLV analyst Arlinda Lee maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO), and raised her …
William Blair analyst John Sonnier maintained an Outperform rating on Halozyme Therapeutics (NASDAQ:HALO), following the company’s third-quarter results. No price target was provided.
